Angiotensin III (human, mouse): Atomic Insights for RAAS and Cardiovascular Disease Modeling

Executive Summary: Angiotensin III (human, mouse) is a bioactive hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe) generated by enzymatic cleavage of angiotensin II in mammalian systems, notably in erythrocytes and tissues (Oliveira et al., 2025). It accounts for approximately 40% of the pressor activity attributed to angiotensin II, while fully retaining aldosterone-stimulating capacity under physiological conditions (DOI). Angiotensin III interacts with AT1 and AT2 receptors, with a relative specificity for AT2, and is implicated in both cardiovascular and neuroendocrine signaling (DOI). Exogenous administration in rodent models reliably induces aldosterone secretion and suppresses renin release, paralleling the effects of angiotensin II (DOI). These properties make Angiotensin III (human, mouse) a uniquely versatile tool for dissecting renin-angiotensin-aldosterone system (RAAS) function, receptor pharmacology, and disease modeling (APExBIO).

Biological Rationale

Angiotensin III (CAS: 13602-53-4) is a physiologically relevant peptide derived from the N-terminal cleavage of angiotensin II, catalyzed by aminopeptidase A and other angiotensinases in blood and tissue environments (Oliveira et al., 2025). The sequence is Arg-Val-Tyr-Ile-His-Pro-Phe (residues 2–8 of angiotensin II). It is integral to the renin-angiotensin-aldosterone system (RAAS), a conserved pathway for cardiovascular and renal homeostasis. While angiotensin II is the principal effector, angiotensin III is responsible for a significant fraction of pressor and aldosterone-stimulating activity. It binds both AT1 and AT2 receptor subtypes, but with enhanced relative activity at AT2 receptors, contributing to vasodilatory, anti-inflammatory, and neuroendocrine effects (DOI).

Unlike angiotensin II, angiotensin III does not require further enzymatic conversion for receptor engagement, making it a direct modulator in physiological and pathophysiological contexts. Experimental data in both human and rodent systems confirm its role in blood pressure modulation, sodium balance, and central nervous system signaling. The robust solubility and stability profile of APExBIO’s Angiotensin III (human, mouse) (A1043), with ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO, supports its use in diverse assay systems (APExBIO product page).

Mechanism of Action of Angiotensin III (human, mouse)

Angiotensin III binds to both AT1 and AT2 receptors, which are G protein-coupled receptors (GPCRs) distributed throughout vascular, adrenal, renal, and neural tissues (DOI). At the AT1 receptor, angiotensin III induces vasoconstriction, sodium retention, and aldosterone release, mirroring the canonical effects of angiotensin II. At the AT2 receptor, angiotensin III promotes vasodilation and anti-fibrotic signaling, counterbalancing AT1-mediated responses (DOI).

In the adrenal cortex, angiotensin III is a potent inducer of aldosterone synthesis via increased intracellular calcium and activation of steroidogenic enzymes. In brain tissue, it triggers pressor and dipsogenic (thirst-inducing) responses through central RAAS circuits. The peptide also suppresses renin release via negative feedback, further modulating systemic blood pressure (DOI).

Evidence & Benchmarks

• Angiotensin III (2–8) enhances AXL receptor binding of the SARS-CoV-2 spike protein, paralleling and sometimes exceeding the effect of angiotensin II (Oliveira et al., 2025, DOI).
• In rodent models, exogenous Angiotensin III reliably induces aldosterone secretion at levels comparable to angiotensin II at equimolar concentrations (Oliveira et al., 2025, DOI).
• Angiotensin III mediates 40% of the total pressor activity attributed to angiotensin II in vivo, as measured by direct arterial pressure monitoring (Oliveira et al., 2025, DOI).
• Receptor binding assays confirm that Angiotensin III retains full AT2 receptor affinity, with partial AT1 activity, in both human and mouse tissues (Oliveira et al., 2025, DOI).
• The peptide exhibits robust chemical solubility and stability when stored desiccated at -20°C, with optimal handling in water, ethanol, or DMSO (APExBIO product data, product page).

Applications, Limits & Misconceptions

Applications: Angiotensin III (human, mouse) is employed in cardiovascular disease modeling, hypertension research, and neuroendocrine signaling studies. Its unique AT2 receptor engagement makes it a valuable probe for dissecting anti-fibrotic and anti-inflammatory pathways. In SARS-CoV-2 research, angiotensin III’s facilitation of spike–AXL interactions positions it as a molecular tool for studying viral pathogenesis (DOI). Detailed mechanistic analysis and strategic guidance for translational applications are provided in "Angiotensin III (human, mouse): Strategic Leverage of a Next-Gen RAAS Peptide", which this article extends by offering explicit atomic claims and structured experimental benchmarks.

Compared to "Angiotensin III: Unleashing Translational Innovation in Cardiovascular and Viral Models", our present article integrates new peer-reviewed data and clarifies solubility and storage best practices for research reproducibility. For those seeking practical workflows, see "Angiotensin III: Applied Workflows for Cardiovascular Research", which this article updates by specifying evidence-based parameters and current stability data.

Common Pitfalls or Misconceptions

• Angiotensin III is not a substitute for angiotensin II in all contexts; it exhibits only ~40% of the pressor activity and may differ in tissue-specific effects (DOI).
• The peptide should not be stored in solution for extended periods due to risk of hydrolysis and activity loss (see APExBIO guidance).
• Experimental outcomes may vary between species and tissue types due to differential receptor distribution and local metabolism.
• Angiotensin III does not fully replicate the vasoconstrictive effects of angiotensin II in all vascular beds.
• It is not a direct antiviral agent; its role in viral pathogenesis is as a modulator of spike protein–host receptor interactions, not viral inhibition.

Workflow Integration & Parameters

APExBIO’s Angiotensin III (A1043) is supplied as a lyophilized solid with a molecular weight of 931.09 g/mol and the formula C₄₆H₆₆N₁₂O₉. For maximal stability, store desiccated at -20°C. Prepare fresh solutions for each assay session. Solubility exceeds 23.2 mg/mL in water, 43.8 mg/mL in ethanol, and 93.1 mg/mL in DMSO. Avoid repeated freeze-thaw cycles. For in vivo rodent studies, dosing should be referenced against established pressor and aldosterone-inducing activity benchmarks (Oliveira et al., 2025).

Direct receptor binding assays and downstream functional readouts (blood pressure, aldosterone secretion, renin activity) are recommended for mechanistic studies. Employ appropriate controls with angiotensin II and vehicle to delineate specific effects. Detailed workflows and troubleshooting are further elaborated in the internal article "Angiotensin III: Redefining RAAS Peptide Utility for Translational Research", which this article augments by providing recent peer-reviewed evidence and updated handling parameters.

Conclusion & Outlook

Angiotensin III (human, mouse) is an essential RAAS peptide for dissecting cardiovascular, neuroendocrine, and viral pathogenesis pathways. It mediates distinct AT1 and AT2 signaling, retains aldosterone-stimulating potency, and exhibits a unique profile in SARS-CoV-2 receptor biology. APExBIO’s A1043 formulation offers validated purity, solubility, and stability, supporting reproducible results across assays. Future directions include its role as a probe for AT2-targeted therapeutics and as a molecular tool in infectious disease research. For detailed specifications and ordering, refer to the Angiotensin III (human, mouse) product page.